Summary
This paper presents a methodological contribution to address an identified gap in drug discovery pipelines for Mycobacterium abscessus, a clinically significant pathogen. The authors developed persister assays—experimental systems to identify slow-growing or dormant bacterial cells that exhibit extreme drug tolerance—and describe their application to screen for novel compounds with anti-persister activity. The work is positioned as a tool to advance compound progression in Mab drug development.
Regional applicability
This laboratory methodology is relevant to UK pharmaceutical and microbiological research institutions engaged in antimicrobial discovery, particularly those working on non-tuberculous mycobacterial infections. It may inform best practice in drug screening protocols adopted by UK-based researchers.
Key measures
Persister cell tolerance to antimicrobial compounds; anti-persister compound activity
Outcomes reported
The study describes development of persister assays to address a gap in Mycobacterium abscessus drug discovery. The assays enable identification of novel compounds with anti-persister activity.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.